The next follow-up here is something you hinted at earlier, which is what do we know about other effects for sglt2 is outside of just the glycemic control. Yeah. I think this is where things do get a little bit interesting because we've talked about metformin. I think people are already familiar with the idea that okay metformin is kind of like bread and butter early intervention type 2 diabetes, but that's not really the reason people are excited about it. People are excited about meant for People talk about in people ask me about it because the belief is that it's doing something Beyond regulating blood sugar and I think to a lesser extent in the Public's eye, but probably to a greater extent in the scientific eye. The excitement is the same for sglt2 Inhibitors. That's interesting isn't it? Right? The public is way more interested about metformin. I think the scientific Community sees much more promise than sglt2 Inhibitors at least on average and that's based on my very unofficial survey of this. Why is that one of the things is that the ITP the interventions testing program has found a clear difference between them will talk about that in a second. I'm sure but the other one is just looking at the really clear differences in human clinical trials for the advantages associated with sglt2 Inhibitors in terms of major adverse cardiac events, what are called mace so if you look at people with or without is the big Point without tea 2D sglt2 Inhibitors have been shown to decrease the risk of hospitalization and death for heart failure patients with reduced ejection fraction and improve basically all cardiovascular outcomes in patients with heart failure who have preserved EF so you take people who have reduced ejection fraction. So what does that mean? So the heart pumps and we can measure with an ultrasound how much blood comes out of the heart with each pump. So if you're at rest that number might be 40% 50% and if you're under great stress or when you're exercising using one of the tools that the body has to increase cardiac output is not just to beat faster but also to beat with greater contractility and get more ejection of blood volume. Well heart failure is basically a condition in which action fraction goes down and when ejection fraction gets low enough twenty percent 15 percent you're in a lot of difficulty and what's been demonstrated and this has been demonstrated repeatedly is that when patients have heart failure with or without reduction in EF outcomes are better if they're taking sglt2 Inhibitors, even if they are not Patients with type 2 diabetes again. I think there are lots of potential reasons why we might see that I think it probably has to do with the reduction in blood pressure, but it may have to do with other things as well which we could explore.